875288-77-0

Upstream product

• 186581-53-3 diazomethane 
• 31820-15-2 Docosa-4,7,10,13,16,19-hexainsaeure 
• 67-56-1 methanol 
• 6217-54-5 docosahexaenoic acid 
• 169900-28-1 (Z,Z)-10-oxodeca-4,7-dienoic acid methyl ester 
• 928-96-1 (Z)-3-Hexen-1-ol 
• 84254-20-6 1-bromo-3-hexene 
• 13395-34-1 (3-(methoxycarbonyl)propyl)triphenylphosphonium bromide 
• 81345-02-0 (3Z,6Z,9Z)-dodecatrien-1-ol 
• 21676-05-1 (3Z)-3-hexenyltriphenylphosphonium bromide 
• 162758-88-5 (Z)-6,6-diisopropoxyhex-3-en-1-al 
• 169900-26-9 (Z,Z,Z)-1-bromododeca-3,6,9-triene 
• 169900-23-6 (Z,Z,Z)-dodeca-3,6,9-trien-1-al 
• 169900-22-5 (Z,Z,Z)-1,1-diisopropoxydodeca-3,6,9-triene 

Relevant academic research and scientific papers

Synthesis of methyl (5Z,8Z,11Z,14Z,17E)-eicosapentaenoate and methyl (4Z,7Z,10Z,13Z,16Z,19E)-docosahexaenoate

(3Z,6Z,9Z,12E)-Pentadecatetraenal, a common intermediate in the synthesis of methyl Δ17t EPA and methyl Δ19t DHA, was obtained by copper(I)-catalyzed coupling between the Grignard reagent of 1,1-diethoxy-3-butyne and (Z,E)-1-bromo-5,8-undecadien-2-yne fol

Enzymatic studies with 3-oxa n-3 DPA

Cyclooxygenase-2 and several lipoxygenases convert polyunsaturated fatty acids into a large variety of products. During inflammatory processes, these enzymes form several distinct families of specialized pro-resolving lipid mediators possessing potent anti-inflammatory and pro-resolving effects. These mediators have attracted a great interest as leads in drug discovery and have recently been the subject of biosynthetic pathway studies using docosahexaenoic and n-3 docosapentaenoic acid as substrates. Herein we present enzymatic studies with cyclooxygenase-2 and 5-, 12- and 15-lipoxygenase enzymes using 3-oxa n-3 DPA as a synthetic mimic of n-3 docosapentaenoic acid. Structural elucidation based on data from RP-HPLC UV and LC/MS-MS experiments enabled the identification of novel enzymatically formed products. These findings constitute the basis for further biosynthetic studies towards understanding the mechanisms regulating substrate utilization in the biosynthesis of specialized pro-resolving lipid mediators.

Trans Lipid Library: Synthesis of Docosahexaenoic Acid (DHA) Monotrans Isomers and Regioisomer Identification in DHA-Containing Supplements

Docosahexaenoic acid (DHA) is a semiessential polyunsaturated fatty acid (PUFA) for eukaryotic cells that is found in natural sources such as fish and algal oils and widely used as an ingredient for omega-3 containing foods or supplements. DHA effects are

Sterols and Fatty Acids of the Harmful Dinoflagellate Cochlodinium polykrikoides

Sterol and fatty acid compositions were determined for Cochlodinium polykrikoides, a toxic, bloom-forming dinoflagellate of global significance. The major sterols were dinosterol (40% of total sterols), dihydrodinosterol (32%), and the rare 4α-methyl Δ8(14) sterol, amphisterol (23%). A minor sterol, 4α-methylergost-24(28)-enol was also detected (5.0%). The fatty acids had a high proportion of PUFAs (47%), consisting mainly of EPA (20%) and the relatively uncommon octadecapentaenoic acid (18: 5, 22%). While unlikely to be responsible for toxicity to fish, these lipids may contribute to the deleterious effects of this alga to invertebrates.

GC-EI-MS analysis of fatty acid composition in brain and serum of twitcher mouse

Globoid cell leukodystrophy or Krabbe disease is an inherited autosomal recessive disorder caused by mutations in the galactosylceramidase gene. The objective of the study was to present information about the fatty acid (FA) composition of the brain and serum of twitcher mice, a mouse model of Krabbe disease, compared to wild type, in order to identify biomarker of disease progression. We defined the FA profiles by identifying the main components present in serum and brain using GC-EI-MS analysis. The FA percentage composition was measured and data were analyzed considering the disease and the mouse age as experimental factors. Significant correlations were established, both in brain and in serum, in the fatty acid percentage composition of twitcher compared to wild type mice. The most abundant saturated fatty acid in brain was the palmitic acid (C16:0) with mean values significantly increased in twitcher mouse (p = 0.0142); moreover, three monounsaturated, three polyunsaturated (PUFA) and a plasmalogen were significantly correlated to disease. In the serum highly significant differences were observed between the two groups for three polyunsaturated fatty acids. In fact, the docosahexaenoic acid (C22:6n3c) content was significantly increased (p = 0.0116), while the C20 PUFA (C20:3n6c and C20:5n3c) were significantly decreased in twitcher serum samples. Our study shows a specific FA profile that may help to define a possible pattern that could distinguish between twitcher and wild type; these data are likely to provide insight in the identification of new biomarkers to monitor the disease progression and thereby permit the critical analysis of therapeutic approaches.

METHOD FOR THE SYNTHESIS OF DHA

A method for preparing docosahexaenoic acid (DHA). The method comprises coupling a compound represented by Formula I with a compound represented by Formula II followed by partial hydrogenation to obtain a compound represented by Formula III. The compound represented by Formula III acts as a DHA precursor and thus can be hydrolysed to obtain DHA. Novel starting materials represented by Formula I and Formula II, and synthetic routes for preparing the same are also provided.

Compositions and methods of omega polyunsaturated fatty acids for the treatment of oral diseases

The invention discloses a novel discovery of anti-microbial activity against oral bacteria, which can be applied for controlling and preventing oral diseases, of omega-3, omega-6, and omega-9 fatty acids, but not limited to omega-3, omega-6, and omega-9 fatty acids; omega-3, omega-6, and omega-9 fatty acid methyl esters, and omega-3, omega-6, omega-9 fatty acid ethyl esters and their application method. The application of this discovery includes the preparation of drugs, dietary supplements, food and daily necessities with oral health care and therapeutic effects.

DIRECT METHOD AND REAGENT KITS FOR FATTY ACID ESTER SYNTHESIS

Provided are efficient, cost-effective and water tolerant methods (e.g., single-vial methods) for preparing fatty acid esters from organic matter, comprising: obtaining organic matter comprising at least one fat substituent, contacting the organic matter in a reaction mixture with a basic solution under conditions suitable to provide for hydrolytic release of monomeric fatty acids from the at least one fat substituent to provide a base-treated reaction mixture, and esterifying the monomeric fatty acids of the base-treated reaction mixture by acidification of the reaction mixture and treating in the presence of an organic alcohol to provide fatty acid esters. The methods optionally further comprise, prior to esterifying, neutralizing the base-treated reaction mixture to provide for neutralized fatty acids, separating the neutralized fatty acids from the neutralized reaction mixture, and dissolving the separated fatty acids in the esterification reaction mixture. Also provided are related methods and kits for fat analysis.